Skip to main content

Table 3 The reported AEs of included studies

From: Aripiprazole for the treatment of tic disorders in children: a systematic review and meta-analysis

System

Aripiprazole

Haloperidol

Tiapride

Risperidone

Neuromuscular system and mental symptom

Drowsiness:5.1 %(5/98)–58.1 %(18/31);

Drowsiness: 6.67 %(2/30)–82.4 %(14/17);

Dizziness: 3.1 %(3/97)–6.67 %(2/30);

Drowsiness:17.2 %(5/29);

Extrapyramidal symptoms: 6.45 %(2/33)–19.4 %(6/31);

Extrapyramidal symptoms: 40 %(12/30)–43.6 %(17/39);

Drowsiness: 3.23 %(1/31)–5.2 %(5/97);

Fatigue: 3.4 %(1/29);

Headache: 2 %(2/98)–16.1 %(5/31);

Tremor: 19.4 %(6/31)–22.5 %(9/40);

Anxiety: 13.3 %(4/30);

Dizziness: 3.4 %(1/29);

Akathisia:3.33 %(1/30)–6.3 %(2/32);

Headache: 58.8 %(10/17);

Sedation: 6.67 %(2/30);

Nausea: 3.4 %(1/29);

Anxiety: 2 %(2/98)–6.45 %(2/31); Tremor: 3.23 %(1/31)–5 %(2/40);

Dizziness: 11.8 %(2/17);

Akathisia: 6.67 %(2/30);

Fatigue: 2 %(2/98)–9.7 %(3/31);

Emotional hypersensitivity: 11.8 %(2/17);

Fatigue: 3.1 %(3/97);

Dizziness: 2.44 %(1/41)–6.5 %(2/31);

Insomnia: 11.8 %(2/17); Irritability:11.8 %(2/17); Fatigue: 7.69 %(3/39); Nightmare: 5.9 %(1/17);

Headache: 2.1 %(2/97);

Insomnia: 1 %(1/98)–3.2 %(1/31); Sedation:12.5 %(4/32);

 

Insomnia : 2.1 %(2/97);

Slowness: 6.5 %(2/31); Tiredness: 4.88 %(2/41);

Emotional hypersensitivity: 3.2 %(1/31); Irritability: 3.2 % (1/31);

Nightmare: 3.2 %(1/31)

Digestive system

Increased appetite: 3.2 %(1/31)–25.8 %(8/31);

Nausea/vomiting: 23.5 %(4/17);

Nausea: 3.1 %(3/97)–13.3 %(4/30);

Increased appetite:

Anorexia: 4.1 %(4/98)–15 %(6/40); Nausea: 2 %(2/98)–18.8 %(6/32);

Nausea: 16.1 %(5/31);

Anorexia: 3.23 %(1/31)–4.1 %(4/97);

27.6 %(8/29);

Nausea/vomiting:1 %(1/98)–29 %(9/31);

Gastrointestinal disturbances: 11.8 %(2/17);

Nausea/vomiting: 2.1 %(2/97);

Abdominal pain: 6.9 %(2/29);

Decreased Appetite: 12.9 %(4/31); Abdominal pain 9.7 %(3/31);

Anorexia: 7.5 %(3/40)–11.8 %(2/17);

Gastrointestinal disturbances: 6.5 %(2/31); Dyspepsia: 3.1 %(1/32);

Constipation: 6.45 %(2/31);

Abnormal liver function: 1 %(1/98);

Increased appetite: 5.9 %(1/17)

Ocular region

Blurred vision: 3.2 %(1/31)–9.7 % (3/31)

-

-

Blurred vision: 10.3 %(3/29);

Endocrine system

Weight gain: 1 %(1/98); Polydipsia: 3.2 %(1/31)

-

-

-

Urinary system

Nocturia: 3.2 %(1/31)

Nocturia: 5.9 %(1/17);

Nocturia: 1 %(1/97)–3.23 %(1/31);

Diurnal Urinary incontinency: 13.8 %(4/29);

Cardiovascular system

Elecrocardiogram QT prolonged: 6.3 %(2/32);

Electrocardiographic abnormality: 6.45 %(2/31)–10 %(4/40);

-

-

Electrocardiographic abnormality: 2.5 %(1/40)–6.45 %(2/31);

Chest discomfort: 11.8 %(2/17)

Chest discomfort: 3.2 % (1/31)

Respiratory system

Nasopharyngitis: 12.5 %(4/32);

-

-

-

Upper respiratory tract infection: 3.1 %(1/32);

Skin

Itches: 3.2 %(1/31);

-

-

Itches: 10.3 %(3/29);

Others

Dry mouth: 6.5 %(2/31)–6.67 %(2/30);

Dry mouth: 5 %(2/40)–19.4 %(6/31);

Dry mouth: 10 %(3/30);

-

Tiredness: 15.4 %(6/39); Joint pain: 11.8 %(2/17);

Febrile sense: 5.9 %(1/17);

School refusal: 5.9 %(1/17);